We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced that it has entered into an agreement with Johnson & Johnson (JNJ - Free Report) to develop and commercialize a first-in-class vaccine candidate against extraintestinal pathogenic E. coli (“ExPEC”).
Per the terms of the agreement, both Sanofi and J&J will co-fund current and future R&D costs to develop the ExPEC vaccine, which is being evaluated in an ongoing late-stage (E.mbrace study). Sanofi will pay $175 million to J&J as an upfront payment for entering into the agreement. J&J will also be eligible to receive potential milestone payments.
The companies also agreed to a profit-share arrangement in six countries — the United States, France, Germany, Italy, Spain and the U.K. For the rest of the world, Sanofi will pay royalties and sales milestones to J&J.
This collaboration with J&J reflects Sanofi’s commitment to advancing its vaccine portfolio and addressing unmet medical needs. The novel ExPEC vaccine will likely complement Sanofi’s older adult vaccine portfolio.
The ongoing E.mbrace study is designed to evaluate the efficacy of the 9-valent ExPEC vaccine (“ExPEC9V”) over placebo in preventing invasive E. coli disease caused by ExPEC9V O-serotypes in older adults (aged 60 years and above). The study is currently enrolling participants.
Shares of Sanofi have increased 10.6% year to date compared with the industry’s 4.2% rise.
Image Source: Zacks Investment Research
ExPEC is a leading cause of sepsis, mainly in older adults. Per the World Health Organization (“WHO”), sepsis is a life-threatening condition wherein the body’s immune system has an extreme response to an infection, thereby causing damage to one’s tissues and organs.
Through the ExPEC vaccine, Sanofi aims to reduce the disease burden on the human body and rising hospitalization costs, thereby positively impacting public health.
In the past 60 days, estimates for Annovis Bio’s 2023 loss per share have narrowed from $4.89 to $4.38. During the same period, the loss estimates per share for 2024 have improved from $3.18 to $2.77. Year to date, shares of Annovis have lost 32.2%.
Earnings of Annovis Bio beat estimates in three of the last four quarters while missing the mark on one occasion, witnessing an earnings surprise of 13.40% on average. In the last reported quarter, Annovis’ earnings beat estimates by 6.14%.
In the past 60 days, estimates for Vaxxinity’s 2023 earnings per share narrowed from 69 cents to 58 cents. During the same period, the loss estimates per share for 2024 have improved from 70 cents to 54 cents. Year to date, shares of Vaxxinityhave lost 9.3%.
Earnings of Vaxxinity beat estimates in three of the trailing four quarters while meeting the mark on one occasion, witnessing an average earnings surprise of 10.94%. In the last reported quarter, Vaxxinity’s earnings beat estimates by 31.25%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
Sanofi (SNY - Free Report) announced that it has entered into an agreement with Johnson & Johnson (JNJ - Free Report) to develop and commercialize a first-in-class vaccine candidate against extraintestinal pathogenic E. coli (“ExPEC”).
Per the terms of the agreement, both Sanofi and J&J will co-fund current and future R&D costs to develop the ExPEC vaccine, which is being evaluated in an ongoing late-stage (E.mbrace study). Sanofi will pay $175 million to J&J as an upfront payment for entering into the agreement. J&J will also be eligible to receive potential milestone payments.
The companies also agreed to a profit-share arrangement in six countries — the United States, France, Germany, Italy, Spain and the U.K. For the rest of the world, Sanofi will pay royalties and sales milestones to J&J.
This collaboration with J&J reflects Sanofi’s commitment to advancing its vaccine portfolio and addressing unmet medical needs. The novel ExPEC vaccine will likely complement Sanofi’s older adult vaccine portfolio.
The ongoing E.mbrace study is designed to evaluate the efficacy of the 9-valent ExPEC vaccine (“ExPEC9V”) over placebo in preventing invasive E. coli disease caused by ExPEC9V O-serotypes in older adults (aged 60 years and above). The study is currently enrolling participants.
Shares of Sanofi have increased 10.6% year to date compared with the industry’s 4.2% rise.
Image Source: Zacks Investment Research
ExPEC is a leading cause of sepsis, mainly in older adults. Per the World Health Organization (“WHO”), sepsis is a life-threatening condition wherein the body’s immune system has an extreme response to an infection, thereby causing damage to one’s tissues and organs.
Through the ExPEC vaccine, Sanofi aims to reduce the disease burden on the human body and rising hospitalization costs, thereby positively impacting public health.
Sanofi Price
Sanofi price | Sanofi Quote
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).A couple of better-ranked stocks in the overall healthcare sector include Annovis Bio (ANVS - Free Report) and Vaxxinity (VAXX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Annovis Bio’s 2023 loss per share have narrowed from $4.89 to $4.38. During the same period, the loss estimates per share for 2024 have improved from $3.18 to $2.77. Year to date, shares of Annovis have lost 32.2%.
Earnings of Annovis Bio beat estimates in three of the last four quarters while missing the mark on one occasion, witnessing an earnings surprise of 13.40% on average. In the last reported quarter, Annovis’ earnings beat estimates by 6.14%.
In the past 60 days, estimates for Vaxxinity’s 2023 earnings per share narrowed from 69 cents to 58 cents. During the same period, the loss estimates per share for 2024 have improved from 70 cents to 54 cents. Year to date, shares of Vaxxinityhave lost 9.3%.
Earnings of Vaxxinity beat estimates in three of the trailing four quarters while meeting the mark on one occasion, witnessing an average earnings surprise of 10.94%. In the last reported quarter, Vaxxinity’s earnings beat estimates by 31.25%.